A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu et al. · Journal of the National Comprehensive Cancer Network · 2010 · 1.2K citations

Medicine, Oncology, Pathology +17

Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC

Masahiro Tsuboi, Roy S. Herbst, Thomas John et al. · New England Journal of Medicine · 2023 · 612 citations

Medicine, Oncology, Pharmacology +17

Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Paolo G. Casali, Jean‐Yves Blay, N. Abecassis et al. · Annals of Oncology · 2021 · 563 citations · Full text

Medicine, Oncology, Surgery +12

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Reinhard Dummer, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2020 · 407 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

Jean‐Yves Blay, Axel Le Cesne, Isabelle Ray‐Coquard et al. · Journal of Clinical Oncology · 2007 · 391 citations

Medicine, Oncology, Pharmacotherapy +11